Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue

Cancer-related Fatigue Clinical Trial

Official title:

A Pilot, Randomized Double-Blind Placebo-Controlled Crossover Study of Synthetic Thyrotropin Releasing Hormone (TRH) Administration for the Treatment of Fatigue in Patients With Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00790296
• Other study ID #: 05-269-2
• Secondary ID: 601
• Status: Terminated
• Phase: Phase 2
• First received: November 10, 2008
• Last updated: December 4, 2017
• Start date: December 2006
• Est. completion date: March 2010

Study information

• Verified date: December 2017
• Source: UConn Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue.

The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: March 2010
• Est. primary completion date: February 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of cancer who have undergone or are currently undergoing radiation or chemotherapy therapy and are expected not to have any significant change in cancer treatment sessions during the study period

• Provide written informed consent prior to initiation of any study-related procedures.

• Male or female, 18 years of age or older with a diagnosis of cancer.

• Able to understand and comply with the requirements of the study.

Exclusion criteria:

• Hospitalized patients.

• Patients with an identifiable diagnosis of substance abuse or dependence within 6 months prior to evaluation (except those in full remission, or those with caffeine or nicotine dependence) as defined by DSM-IV criteria.

• Patients with any of the following cardiovascular symptomatology.

• Office systolic BP > 160mmHg and/or diastolic BP > 90mmHg.

• Persons with a resting hear rate of > 100 beats per minute

• Persons with a history of chronic stable angina

• Persons with myocardial infarction or unstable angina or vascular surgery within 6 months

• Persons with history of vaso-vagal or other syncopal episodes

• Patients with any known clinically significant cardiac problems

• Patients with any history of stroke or at significant risk for stroke.

• Patients with a history of seizures

• Patients with a history of asthma

• Patients with any clinically significant unstable or inadequately treated co- morbid medical condition or patients currently on medications that would confound evaluation of CF (e.g. diabetes, CHF, history of other cancers) as judged by the investigator.

• Patients with any clinically significant, unstable psychiatric disorder (except mild to moderate depressive or anxiety disorders) or patients on psychotropic medications that would confound CF assessment as judged by the investigator. Patients with history of depressive or anxiety disorders will not be excluded from the study

• Patients with a history of illnesses or treatments that would be expected to significantly alter immune function (viz. HIV infection, systemic lupus erythematosus, patients taking immunosuppressive medications).

• Patients with diseases or on medications that significantly affect the hypothalamic-pituitary-adrenocortical (HPA) axis function (viz. Cushings disease).

• Pregnant patients, breastfeeding or plans to become pregnant during the study

• Patients with known allergy to TRH

• Any other condition, which, in the opinion of the investigator, would make the patient, unsuited for enrollment, confound CF evaluation or could interfere with the patient's participation in the study.

• Patients with medically reversible causes of CF (viz., anemia, hypothyroidism, electrolyte abnormalities etc).

• Patients with potentially treatable associated symptoms dominating the CF scenario such as pain, or sleep disturbances which may have a significant causal relationship to CF.

• Patients identified as pregnant based on the pregnancy test during screening.

• Patients physically unable to complete the walking test (WT) assessment or when the WT would increase risk for medical complications

Related Conditions & MeSH terms

• Cancer-related Fatigue
• Fatigue

Intervention

Drug:
• Thyrotropin releasing hormone (TRH)
0.5mg and 1.5mg
• Placebo
Saline

Locations

Country	Name	City	State
United States	University of Connecticut Health Center	Farmington	Connecticut

Sponsors (3)

Lead Sponsor	Collaborator
UConn Health	Hollfelder foundation, Susan G. Komen Breast Cancer Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Visual Analog Scale for Energy (VAS-E)Score From Baseline to 7 Hrs Post Study Medication Infusion	1 to 100 scale with 1 referring to No Energy and 100 referring to Normal Energy.	Baseline and 7 hours post study medication infusion